Donor · Global Fund
Global Fund: no origin rule, but a qualified manufacturing site
Global Fund policies contain no list of eligible countries of origin and no nationality rule for suppliers. They even rule out national preference. They do, however, look very closely at where and how a health product is made, and which authority has assessed it.
For a supplier of medical devices, diagnostics or laboratory equipment, origin is therefore a different question: the task is not to prove a country but to document a manufacturing site and a recognised authorisation. This guide summarises those requirements from the 2021 procurement guide and the 2023 quality assurance policy.
Updated on 21 October 2026
No national preference
The June 2021 guide requires recipients to use transparent and competitive procedures, and states that national or domestic preference is not acceptable to the Global Fund unless the applicable law requires it. A European or Asian manufacturer can therefore compete on equal terms with a local supplier, as long as its product meets the quality requirements.
The only mandatory geographical anchor is the country of use. Products must comply with its law there and obtain the regulator's authorisations in time: registration, marketing authorisation or import permit as the case may be.
The factory before the country
The quality assurance policy of 15 November 2023 sorts medical devices into 4 risk classes, A to D. Whatever the class, the product must come from a site compliant with ISO 13485, or an equivalent quality system recognised by an authority of a GHTF founding member or by a WHO-listed authority (WLA). The GHTF founding members are the United States, the European Union, Japan, Canada and Australia.
For classes C and D, WHO prequalification, authorisation by one of those authorities or a WLA, or an Expert Review Panel (ERP) recommendation is also needed. An authorisation granted in the European Union can therefore be decisive for a higher-class device. Diagnostics outside that scope, such as microscopes, fall under the ISO 9000 series according to the 2021 guide.
Tests and medicines for HIV, TB and malaria
Tests for HIV, tuberculosis, malaria and co-infections follow a stricter rule: WHO prequalification, recommendation by the WHO programme for tuberculosis, stringent authorisation by an authority of a GHTF founding member, WLA authorisation, or acceptance by the Global Fund on ERP advice. That advice is only valid for 12 months at most, extendable by up to 12 months.
For antiretrovirals, antimalarials and anti-tuberculosis medicines, the guide requires WHO prequalification (option A) or authorisation by a stringent regulatory authority (option B), with the ERP route available on a time-limited basis.
Disclosing manufacturer, site and sanctions
The 2023 policy requires the manufacturer and manufacturing site to appear in all tender and procurement documents. A distributor or sourcing office cannot present a product under its own name alone: the buyer must be able to trace each item to a factory and its certificates.
The Code of Conduct for Suppliers adds a disclosure: before and during the contract, the supplier reports any sanction or suspension imposed by a major financing institution such as the United Nations or the World Bank.
From Belgium, Sobetracom builds this file manufacturer by manufacturer: site, ISO 13485 certificate, regulatory authorisation and risk class. The precise requirements of a contract remain those of its tender documents and of the destination country's regulator.
Frequently asked questions
- Does the Global Fund require a country of origin for medical devices?
- No. It requires a manufacturing site compliant with ISO 13485 or equivalent and, for classes C and D, assessment by WHO, an authority of a GHTF founding member, a WLA or the ERP.
- Can a recipient favour a domestic manufacturer?
- The PSM guide rules out national preference unless the applicable law requires it.
- Does the bid need to name the factory?
- Yes. The quality assurance policy requires the manufacturer and manufacturing site to appear in all tender and procurement documents.
Sources
- Fonds mondial, Guide to Global Fund Policies on Procurement and Supply Management of Health Products, juin 2021 (October 2026)
- Fonds mondial, Quality Assurance Policy for Medical Devices (including In-Vitro Diagnostics) and Core Personal Protective Equipment, 15 novembre 2023 (October 2026)
- Fonds mondial, Code of Conduct for Suppliers, 11 février 2021 (October 2026)
This page summarises public sources as of the date shown. It does not replace the official text: check it before committing to a purchase, a bid or a shipment.
